MMH-MAP
Phase 3Small molecule
MMH-MAP is one of 62 small molecule programs targeting Cognitive Disorder. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
279 competitors in Cognitive Impairment
#DrugCompanyPhaseTrials
1Actos
TakedaPhase 3
Farxiga
AstraZenecaPhase 3
Provigil
NNuvo Research GmbH
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Xarelto
WWim Janssens
Phase 3
Viagra
VViatris Specialty LLC
Phase 3
Donepezil Hydrochloride
EisaiPhase 3
Namenda
AbbViePhase 2
Statins
SanofiPhase 3
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MMH-MAP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMateria Medica Holding